New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes using basal insulin (≥42 units/day) plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: EDITION 2 was a multicenter, open-label, two-arm study. Adults receiving basal insulin plus OADs were randomized to Gla-300 or Gla-100 once daily for 6 months. The primary end point was change in HbA1c. The main secondary end point was percentage of participants with one or more nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events from week 9 to month 6. RESULTS: Randomized participants (n = 811) had a mean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg/m2 (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was −0.57% (0.09) for Gla-300 and −0.56% (0.09) for Gla-100 (mean difference −0.01% [95% CI −0.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61–0.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified. CONCLUSIONS: Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but about 7% to 15% of insulin-treated persons with T2D experience at least 1 episode of hypoglycemia per year,1109 and 1% to 2% have severe hypoglycemia.1106,1108”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“Hypoglycemia and weight gain are the most common adverse effects of insulin therapy.1106,1107”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered (179-181).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [181]
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615 · cited 1×
“5 rapidly progressing diabetic retinopathy (which may likely require laser/surgical treatment during the study), end-stage renal disease (defined as those participants requiring dialysis or transplantation (12)), or clinically significant cardiac, hepatic, or other systemic disease.”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“3 Insulin glargine 100 U/mL (Gla-100) is a once-daily, long-acting basal insulin analog, which induces less hypoglycemia than neutral protamine Hagedorn (NPH) insulin (1).”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“adherence to the treatment regimen (7,8).”
Psychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 2×
“After subcutaneous injection, Gla-300 has been shown to have smoother, more stable, and prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100, resulting from an extended release of glargine from the subcutaneous depot (9).”
BackgroundRiddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Self-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
Background
Cited by
Items 201–284 of 284
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Sethi, B. K., Al-Rubeaan, K. A., Ünübol, M., Mabunay, M. A., Berthou, B., Pilorget, V., Vethakkan, S. R., & Frechtel, G. D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01271-7 · Cited by 3
Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3
“05) [44, 49]; whereas three studies reported increased dose of IDeg at the endpoint (P\0.”
Backgroundde Adana, M. S. R., Domínguez, M., Morillas, V., Colomo, N., Mora, M. R. V., Guerrero, M., García‐Escobar, E., Carreira, M., Romero‐Zerbo, S., Linares, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110238 · Cited by 3
Insulin’s Legacy: A Century of Breakthroughs and Innovation
Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 4
Chen, L., Wen, B., Liu, H., Wu, H., Duan, B., Shu, H., Zhang, Q., Wu, X., Li, M., Han, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15814 · Cited by 3
“…events), whereas any or nocturnal documented symptomatic hypogly-caemia (PG ≤ 3.9 mmol/L) was reported in 30.6%-49.6% and 12.4%- 22.6% of participants, respectively, in the EDITION studies, 12,14,15,25 and any documented symptomatic hypoglycaemia occurred in 31.4% of participants in TRANSITION 2.”
InfluentialLingvay, I., Chao, J., Dalal, M. R., & Meneghini, L. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0454 · Cited by 3
Hídvégi, T., Balogh, Z., Vass, V., Kovács, G., & Stella, P. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00746-4 · Cited by 3
Kumar, A., Sharma, S., Gupta, A., Dasgupta, A., Asirvatham, A. J., Talwalkar, P., Das, A., & Mohan, V. (2020) · Journal of Diabetology · doi:10.4103/jod.jod_59_20 · Cited by 3
Edelman, S. V., Goldman, J. D., Malone, D. C., Preblick, R., Munaga, K., Li, X., Gill, J., & Gangi, S. (2023) · Clinical Diabetes · doi:10.2337/cd22-0096 · Cited by 3
Monnier, L., Halimi, S., & Bonnet, F. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30010-4 · Cited by 2
Expanded Basal Insulin Options for Type 2 Diabetes Mellitus
Olin, J. L., & Harris, K. B. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.07.011 · Cited by 2
Landgraf, W., Owens, D. R., Frier, B. M., & Bolli, G. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70231 · Cited by 2
Role of insulin in management of type 2 diabetes mellitus
Patil, S. S., Mehta, M., Thakare, V., Shende, S. S., Shirure, P. A., & Swami, O. C. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20172422 · Cited by 3
Wulfe, S., Janzen, K. M., Addison, J. D., & Kelley, D. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221119187 · Cited by 2
Landgraf, W., Owens, D. R., Frier, B. M., & Bolli, G. B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01608-4 · Cited by 2
“Therefore, the aim of this retrospective analysis was to examine glycemic outcomes in basal insulin (BI) pre-treated study participants withT2D derived from the randomized clinical trials EDITION 2 [11] and EDITION 1 [12], according to T2D subpheno-types.”
MethodThurston, M. M., Galdo, J. A., & Bourg, C. A. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.1.20 · Cited by 2
Hirose, T., Cai, Z., Yeo, K. P., Imori, M., Ohwaki, K., & Imaoka, T. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12667 · Cited by 2
Impact of Dosing Conversion From Basal Insulin to Follow-On Insulin Glargine
Maes, M. L., Ashjian, E. J., Kippes, K. A., Marshall, V., Rida, N., & Thompson, A. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019853957 · Cited by 2
Martinka, E., Uličiansky, V., Mokáň, M., Tkáč, I., Galajda, P., Dókušová, S., & Schroner, Z. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.059 · Cited by 2
Vargas‐Uricoechea, H., & Frías, J. P. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.014 · Cited by 2
Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
Maffeis, C., & Rabbone, I. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00520-3 · Cited by 2
Sawamura, T., Karashima, S., Ohbatake, A., Higashitani, T., Ohmori, A., Sawada, K., Yamamoto, R., Kometani, M., Katsuda, Y., & Yoneda, T. (2024) · Medicina · doi:10.3390/medicina60030450 · Cited by 1
Addison, J. D., Glowacki, B., Kelley, D., Janzen, K. M., & Wulfe, S. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae346 · Cited by 1
Umpierrez, G. E., Pogge, E. K., Li, X., Preblick, R., Gill, J., & Pandya, N. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.133274 · Cited by 1
Mohan, V., Sethi, B. K., Jain, S. M., Sahay, R. K., Balamurugan, R., Murthy, S., Singh, K. P., MENON, S. K., Gadekar, A. V., Salvi, V., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01736-5 · Cited by 1
Dehari, D., Padmakumari, R. G., Tesfaw, G., Fierro, F. A., Ameer, G. A., & Shafikhani, S. H. (2026) · Cells · doi:10.3390/cells15020120 · Cited by 1
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_3 · Cited by 1
Future Drug Treatments for Type 1 Diabetes
Sherr, J. L., Cengiz, E., Name, M. A. V., WEINZIMER, S. A., & Tamborlane, W. V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch66 · Cited by 1
NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
Кононенко, И. В., & Smirnova, O. M. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-20-160-165 · Cited by 1
Consensus on insulin treatment in type 2 diabetes
Borrás, J. A. G., Martín, J. E. S., Mata‐Cases, M., Peralta, F. G., Menéndez, S. A., García, D. F., Millán, C. O., Guisasola, F. Á., García, J. C. F., Loiola, P. E., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.01.003 · Cited by 3
Special aspects of concentrated insulins: basic characteristics and research findings
Demidova, T. Y., & Балутина, О. В. (2019) · Diabetes Mellitus · doi:10.14341/dm10334 · Cited by 2
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
Dyakov, I. N., & Zyryanov, S. K. (2021) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2021-1-4-15 · Cited by 1
Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results
Battelino, T., & Mauricio, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01143-6 · Cited by 1
Hassanein, M. M., Sahay, R. K., Hasan, M. I., Hussain, A., Mittal, V., Riyaz, M., Shaikh, Z., Farishta, F., Mohanasundaram, S., Naqvi, M., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01234-y · Cited by 1
Insulintherapie bei Diabetes mellitus
Lechleitner, M., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Hoppichler, F., Kautzky‐Willer, A., Schernthaner, G., Prager, R., & Wascher, T. C. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0925-1 · Cited by 4
Au-delà des insulines actuelles : des réalisations prometteuses et quelques désillusions
Monnier, L., Colette, C., Azrak, A. E., Essekat, N., & Rochd, D. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.002 · Cited by 2
Zúñiga, C., & Machado‐Duque, M. E. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.4.810 · Cited by 1
Clinical Use of New Insulins and New Insulin Delivery Systems
Lim, T., & Ko, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.242
Takahara, M., Shiraiwa, T., Katakami, N., Matsuoka, T., & Shimomura, I. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12762
Clinical value of glargine 300 U/mL based on randomized trials and routine medical practice
Czupryniak, L., Dzida, G. J., Gumprecht, J., Jarosz-Chobot, P. A., Klupa, T., Szelachowska, M., Wolnik, B., & Syta, A. (2017) · Clinical Diabetology · doi:10.5603/dk.2016.0035
HRAMIAK, I. M., Punthakee, Z., Groleau, M., Javadi, P., Bigot, G., & Woo, V. C. (2017) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000782
“Full details of the methodology, participant selection, and endpoints of the EDITION 1, 2, and 3 studies have been published previously [7-9].”
BackgroundMethodInfluentialGreeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2017.1407097
Halimi, S. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30001-4
Bailey, T. S., Odugbesan, O., Gill, J., Nikonova, E. V., Chao, J., & Reid, T. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0181
Sugiyama, K., Meguro, S., Saisho, Y., Irie, J., Tanaka, M., & Itoh, H. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e01257
Insuline glargine Gla-300 (Toujeo®) : de sa formulation à son utilisation en pratique clinique
Potier, L. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30047-1
Hídvégi, T., Balogh, Z., Vass, V., Kovács, G., & Stella, P. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.19
Greeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · South African Family Practice · doi:10.4102/safp.v60i4.4903
Cohen, C. M., Banon, T., Shalev, V., & Chodick, G. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.124
Mitra, A., Ray, S., & Jayan, S. (2020) · Clinical Diabetology · doi:10.5603/dk.2020.0010
“This is due to a more extended time action profile than Gla-100 resulting in a more stable and sustained glycemic control.”
ResultInfluentialValencia, W. M., Florez, H. J., & Palacio, A. M. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00795-6
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Newer Long-Acting Basal Insulin Preparations
Blonde, L. (2017) · Endocrine Practice · doi:10.1016/s1530-891x(20)43535-9
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Monnier, L., & Halimi, S. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00029-4
Hayek, A. A., Robert, A. A., Saeed, A. H. A., & Dawish, M. A. A. (2022) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514221098415
Galstyan, G. R. (2022) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2022-50-027
Repetto, P., & Ayago, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108584
Actualización sobre insulinas basales disponibles
Orozco‐Beltrán, D. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.insulinas.art2
Gezer, D., & Ecin, S. M. (2024) · Medical Science and Discovery · doi:10.36472/msd.v11i3.1133
Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies
Monnier, L., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.02.002
Kiran, G., Sastry, N. G., Kumar, G., Dilipkumar, S., Kalva, L. T., & Sireesha, G. (2024) · International Journal of Medical Arts · doi:10.21608/ijma.2024.271812.1938
“We separated the HbA1c levels for the patients who kept on Gla-100 into the following categories: 7.2 [22], 7.2-7.6 [20], and 7.7% [18].”
BackgroundInfluentialGlargin U300'ün etkinliğinin geriye yönelik olarak değerlendirilmesi: Tek merkez deneyimi
Gezer, D., & YURTSEVER, A. S. (2023) · Mersin üniversitesi sağlık bilimleri dergisi/Mersin üniversitesi sağlık bilimleri dergisi
Kelley, D., Addison, J. D., Janzen, K. M., & Wulfe, S. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1997
Modern insulin treatment for type 2 diabetes
Grønlund, E., Lund, L., Vilsbøll, T., & Hædersdal, S. (2024) · Ugeskrift for Læger · doi:10.61409/v03240172
Tsai, P., Lin, C., Huang, Y., Chen, H., & Lin, Y. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12909
Chen, L., Wan, H., Han, J., Yang, C., Shao, H., Li, J., Yan, W., Xiao, J., Sun, Y., Li, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16144
“…analysis also support the findings of other Gla-300 studies in individuals with T2D uncontrolled on previous BI, including RCTs such as the EDITION 2 and EDITION JP2 studies 3,7 as well as real-world investigations, such as the TOP 2 and DELIVER 2 studies and the REALI pooled database analysis.”
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Insulinothérapie basale: pourquoi des objectifs glycémiques ambitieux?
Roussel, R. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30060-2
Aktuelles: Insulintherapie unter Bezugnahme auf die Leitlinienempfehlungen der ÖDG 2016
Lechleitner, M. (2016) · Journal für Kardiologie (Krause & Pachernegg GmbH)
(IdISPa), I. D. S. D. P. (2015) · Hispana
Aktuelles: Anwendung moderner Basalinsuline bei alten Menschen mit Typ-2-Diabetes
Dewerth, A. (2019) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Aktuelles: Insulin glargin U300 – ein Basalinsulin der nächsten Generation
Luger, A. (2015) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Krings, F. J. (2023) · BCU Open Access Repository (Birmingham City University)
Chen, L., Zhang, Q., Duan, B., Wu, X., Wan, H., WEN, B., Han, J., Liu, H., Yang, C., Liu, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70420
Pscherer, S., Fritsche, A., Anderten, H., Pegelow, K., Han, H. Y., Pfohl, M., & Seufert, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70417
Dong, R., Liu, H., Gu, L., Zhao, Q., Luo, C., Zhang, T., Kou, X., Hu, Y., Shi, B., Guo, H., et al. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02291-1
“Previous research on IDeg or IGlar U300 has primarily focused on their long-term efficacy and safety compared to first-generation long-acting insulin analogues, with only a limited number of head-to-head comparisons with inconsistent results [13, 14].”
Basheer, E. M., & Aladul, M. I. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030021
Metadata
- Authors
- Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C.
- Affiliations
- Department of Medicine, University of Helsinki, and Minerva Foundation Institute for Medical Research, Helsinki, Finland
- Park Nicollet Health Services (US)
- Sanofi (Germany) (DE)
- Sanofi, Warsaw, Poland
- Sanofi, Paris, France
- Oregon Health & Science University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-11-08
- Volume
- 37
- Issue
- 12
- Pages
- 3235-3243
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4230570152
- Cited by
- 274
- References
- 17
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 19 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 47 · 2017: 33 · 2016: 40 · 2015: 23 · 2014: 2
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, type 2 diabetes, basal insulin, oral antidiabetic drugs, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain, insulin dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.